J&J Eyes $20B Apollo Deal to Offload Hips-and-Knees Unit

Johnson & Johnson is in advanced talks to unload its hips-and-knees orthopedic business to private equity giant Apollo Global Management in a deal valued at around $20 billion. If it closes, this would rank among the largest healthcare divestitures of the year — and a major signal that J&J is doubling down on its pharmaceutical and MedTech focus rather than sprawling across every corner of medicine.

For traders, the headline is simple: J&J wants to get leaner. Shedding a mature, lower-margin orthopedics unit frees up capital for higher-growth plays — think oncology drugs and surgical robotics. That's the kind of portfolio reshaping that tends to get rewarded with a multiple expansion over time, especially when management pairs it with buybacks or acquisitions in priority segments.

Read more Anderson's Progress Real, Even When the Scoreboard Disagrees →

Apollo's interest here is equally telling. Private equity has been aggressively circling healthcare assets that generate steady, predictable cash flows — and orthopedic implants fit that profile almost perfectly. Hip and knee replacements aren't going away; an aging global population virtually guarantees volume growth for years. Apollo sees a business it can optimize and potentially relist at a premium later.

The $20 billion price tag puts this firmly in blockbuster territory. Negotiations are ongoing, meaning terms could shift or the deal could fall apart — that's the risk you carry if you're trading around this news. Watch for any official announcement or breakdown in talks, because either outcome moves the stock.

Continue reading at Yahoo Finance